Commercial Expansion

Dragonfly Energy Hires Fleet Veteran Keller for National Sales Push

Image
Dragonfly Energy Hires Fleet Veteran Keller for National Sales Push

RENO – October 27, 2026 -- Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has appointed Robert Keller, a sales executive with nearly four decades of experience, as Director of National Fleet Sales to strengthen its commercial presence in heavy-duty trucking.

Keller brings Volvo Trucks and telematics background to the role

Keller's career spans fleet operations, commercial vehicle sales, telematics and fleet technology. He previously held leadership and sales roles at Volvo Trucks North America, Road Ready Advanced Telematics and Fleetworthy Solutions, Inc. According to the company, he has built strategic relationships with some of the largest commercial fleets in the U.S. and helped grow transportation technology businesses.

THINK Surgical Names Rick McDowell VP of Sales

Image
THINK Surgical Names Rick McDowell VP of Sales

Fremont, Calif. – September 22, 2026 -- THINK Surgical, Inc. has appointed Rick McDowell as Vice President, Sales, tasking him with leading the orthopedic robotics maker's national sales organization as it scales commercial operations.

McDowell reports directly to Executive Vice President Chris Marrus

McDowell will drive market strategy and growth for THINK Surgical's commercial team, reporting to Chris Marrus. He arrives with more than 20 years in medical device commercialization, clinical strategy, and capital sales across the surgical robotics sector.

Neurent Medical Secures €25M Debt Facility From Claret Capital

Image
Neurent Medical Secures €25M Debt Facility From Claret Capital

Galway, Ireland – – September 14, 2026 -- Neurent Medical has secured a €25 million growth debt financing facility from Claret Capital Partners to accelerate commercial expansion of its NEUROMARK® System for chronic rhinitis treatment.

Debt facility follows €62.5 million Series C round completed earlier in 2026

The new €25 million facility builds on Neurent Medical's €62.5 million Series C financing round, which closed earlier this year. The combined capital reinforces the company's position in minimally invasive treatments for chronic inflammatory sinonasal diseases.